A new series of 9-(1-(substituted-benzyl)piperidin-4-yl)-2-chloro-9H-purin-6-amine derivatives were designed, synthesized, and characterized on the basis of 1 H-NMR, 13 C-NMR, and mass spectra. The newly synthesized compounds were evaluated for the inhibition activity against acetylcholinesterase (AChE). Biological results revealed that four compounds among them showed moderate activities against AChE with inhibitory percentage more than 10% at 100 M. Further pharmacology investigation towards other pathological routes in AD is currently underway.
Introduction
Since a cholinergic hypothesis has been postulated as a crucial element in Alzheimer's disease (AD) symptoms etiology, catalytic acetylcholinesterase (AChE) inhibitors have constituted until today the main drugs used against AD [1] . Reversible inhibition of brain AChE by anti-AD drugs such as tacrine [2] , donepezil ( Figure 1 ) [3] , and huperzine [4] increases the AChE levels and improves neurotransmission in cholinergic synapses [5] . Since AChE plays a proaggregating (noncatalytic) role to accelerating -amyloid peptide (A ) aggregation and deposition into the fibrils, inhibition of AChE is still the most successful therapeutic strategy for the symptomatic treatment of AD and its progression [6] . The search for novel AChE inhibitors with improved biological profiles continues to be of great interest to medicinal chemists.
In the past few years, a group of 2,4-disubstituted pyrimidine derivatives were reported as cholinesterase inhibitors and agents targeting multiple pathological routes in AD. Particularly, compound PY-1 was identified as the lead candidate with a dual ChE (AChE IC 50 = 9.9 M; BuChE IC 50 = 11.4 M), A -aggregation (AChE-induced = 59.3%; self-induced = 17.4% at 100 M), and BACE-1 (34% inhibition at 10 M) inhibitory profile along with good cell viability (81.0% neuroblastoma cell viability at 40 M) [7] [8] [9] [10] . Meanwhile, o-fluorophenyl methyl derived triazole PU2012051296, effectively suppressed A -induced neurotoxicity in hippocampal slice cultures. Importantly, the neuroprotective effect of compound PU2012051296 is comparable to those of flavopiridol and roscovitine, state of the art pharmaceuticals [11] .
The refinement of the central core in bioactive molecules combined with introducing privileged substituents is a common practice in medicinal chemistry to find proprietary and novel hits. Based on the considerable similarities of these lead compounds, a fragment-based design was employed to identify alternative chemotypes ( Figure 2) . Meanwhile, in current drug research field, substituted purines have attracted considerable attention from the medicinal chemists in recent years, owing to the high number of positive hits encountered with this heterocycle. In this paper, a novel 
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IC 50 = 5.5 M (AChE); PU2012051296 59% inhibition of hAChE-induced aggregation of A (1-40) fibrils (at 100 M).
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series of 9-(1-(substituted-benzyl)piperidin-4-yl)-2-chloro-9H-purin-6-amine derivatives were designed, synthesized, and evaluated for the inhibition activity against AChE.
Results and Discussion

Chemistry.
The synthetic route of the target compounds is outlined in Scheme 1. which was started from commercially available materials and completed using well established methods. Initially, N-(3,4-dimethoxybenzyl)-2-chloro-9H-purin-6-amine (2a) and N-(benzo[d] [1, 3] dioxol-5-ylmethyl)-2-chloro-9H-purin-6-amine (2b) intermediates were synthesized from the starting material 2,6-dichloro-9H-purine (1) by a nucleophilic aromatic substitution reaction at the C-6 position using either (3,4-dimethoxyphenyl) methanamine or benzo[d] [1, 3] dioxol-5-ylmethanamine in the presence of triethylamine (TEA). The reaction was run in t-BuOH at 60 ∘ C for 30 min. Intermediates 6 and 7 were obtained in good yields ranging (90.5% and 89.7%) (Scheme 1) [7] [8] [9] [10] . In the meantime, tert-butyl 4-hydroxypiperidine-1-carboxylate (4) was synthesized according to the reported procedure [12] . Then treatment of intermediate 4 with compound 2a or 2b in the presence of NaH afforded tert-butyl
purin-9-yl)piperidine-1-carboxylate (5b), respectively. The deprotection of the tert-butoxycarbonyl (t-Boc) group of 5a and 5b was accomplished using trifluoroacetic acid (TFA) in dichloromethane (DCM) to yield N-(3,4-dimethoxybenzyl)-2-chloro-9-(piperidin-4-yl)-9H-purin-6-amine (6a) and N-(benzo[d] [1, 3] dioxol-5-ylmethyl)-2-chloro-9-(piperidin-4-yl)-9H-purin-6-amine (6b), respectively, in good yield (91% and 87%). In the last step, the alkylation reaction of piperidine at NH position with various substituted benzyl chloride (bromine) afforded the target compounds. The newly synthesized compounds were characterized by physicochemical and spectral means, and the MS and NMR spectral data are found in agreement with the assigned molecular structures.
Cholinesterase Inhibition.
All the newly synthesized compounds (7a1-a13, 7b1-b13) were evaluated for their inhibitory activities toward AChE using an in vitro assay based on the reported protocol [7] [8] [9] [10] , in comparison with donepezil as standard drug. The anticholinesterase activities are summarized in Table 1 . Preliminary results in Table 1 revealed that compound 7b9 with a 3-cyanobenzyl group in the benzo[d] [1, 3] dioxol-5-yl series displayed the highest AChE inhibitory activity (15.42% at 100 M) among all the tested compounds. Besides, compounds 7a1, 7a7, and 7b10 with inhibitory percentage more than 10% at 100 M showed similar activities with compound 7b9 against AChE. Generally, all the compounds in both 3,4-dimethoxyphenyl and benzo[d] [1, 3] dioxol-5-yl series demonstrated much lower inhibitory activity toward AChE than the reference drug donepezil (80.07% at 100 M). Obviously, the activity of the compounds depends upon the nature of the substituents attached with purine ring. Even small modifications in every series can decrease and even lost their activity against AChE. Therefore, the coherent structure-activity relationship will be afforded by further pharmacology investigation, which is currently underway in our lab.
Conclusion
In summary, a novel series of 9-(1-(substituted-benzyl) piperidin-4-yl)-2-chloro-9H-purin-6-amine derivatives were designed and synthesized, and their AChE inhibitory activities were preliminary examined. Biological assay demonstrated that four compounds showed moderate activities against AChE with inhibitory percentage more than 10% at 100 M. Further investigation of other bioactivities associated with AD of this series is ongoing work within our group and will be reported in due course.
Experimental Section
4.1. Chemistry. All melting points were determined on a micromelting point apparatus and are uncorrected. 1 H-NMR and 13 C-NMR spectra were obtained on a Bruker Avance-400 NMR-spectrometer in the indicated solvents. Chemical shifts are expressed in units and TMS as internal reference. Mass spectra were taken on an LC Autosampler Device: Standard G1313A instrument. TLC was performed on Silica Gel GF254 for TLC (Merck) and spots were visualized by iodin evapours or by irradiation with UV light ( = 254 nm). Flash column chromatography was performed on column packed with Silica Gel60 (230-400 mesh). Solvents were reagent grade and when necessary were purified and dried by standard methods. Concentration of the reaction solutions involved the use of rotary evaporator at reduced pressure.
General Procedure for the Preparation of 2a and
2b. 2,6-Dichloro-9-H-purine (1.89 g, 10 mmol) and Et 3 N (1.6 mL, 11 mmol) was dissolved in t-BuOH (50 mL), and the mixed solution of 3,4-dimethoxybenzylamine (1a, 1.50 mL, 10 mmol) and t-BuOH (20 mL) or benzo[d] [1, 3] dioxol-5-ylmethanamine (1b, 1.27 mL, 10 mmol) and t-BuOH (20 mL) was slowly added to the previous solution in 20 min at 60 ∘ C. The resulting mixture was stirred at 60 ∘ C for 30 min. Then the reaction mixture was poured into cold H 2 O (100 mL), the resulting precipitate was collected by filtration underreduced pressure and washed sequentially with H 2 O then dried to give the corresponding product 2a as a white power with yield of 90.5% or 2b as a white power with yield of 89.7%. 44 mmol) and DCM (20 mL) was slowly added to the mixed solution in 30 min at 60 ∘ C. The mixtures were stirred at 0 ∘ C overnight. Then the reaction solution was alkalized to PH = 9 with NaHCO 3 . The solution was washed by water (50 mL) then extracted with DCM (3 × 15 mL). Combined organic phase dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure to give the product 4 as white solid. Yield: 94.3%.
General Procedure for the Preparation of 4. N-Boc-4-
3,4-Dimethoxyphenyl 3,4-Dimethoxyphenyl 4-Methoxybenzyl 2,6-Dicholobenzyl NA NA 7a12 3,4-Dimethoxyphenyl 2,4,6-Trimethylbenzyl NA 7a13 3,4-Dimethoxyphenyl 2-Fluorobenzyl 4.02 7b1 Benzo[d][1, 3]dioxol-5-yl 3-Chlorobenzyl NA 7b2 Benzo[d][1, 3]dioxol-5-yl 3-Bromobenzyl 0.09 7b3 Benzo[d][1, 3]dioxol-5-yl 4-Cyanobenzyl NA 7b4 Benzo[d][1, 3]dioxol-5-yl 4-Nitrobenzyl NA 7b5 Benzo[d][1, 3]dioxol-5-yl 3-Fluorobenzyl 0.14 7b6 Benzo[d][1, 3]dioxol-5-yl Pyridine-4-yl-methyl NA 7b7 Benzo[d][1, 3]dioxol-5-yl Benzyl 7.55 7b8 Benzo[d][1, 3]dioxol-5-yl 4-Bromobenzyl 7.29 7b9 Benzo[d][1, 3]dioxol-5-yl 3-Cyanobenzyl 15.42 7b10 Benzo[d][1, 3]dioxol-5-yl 4-Methoxybenzyl 11.21 7b11 Benzo[d][1, 3]dioxol-5-yl 2,6-Dicholobenzyl 3.80 7b12 Benzo[d][1, 3]dioxol-5-yl 2,4,6-Trimethylbenzyl 1.51 7b13 Benzo[d][1, 3]dioxol-5-yl 2-
General Procedure for the Preparation of 5a
and 5b.
.03 g, 10 mmol) was dissolved in DMF (60 mL) and added 60% dispersion NaH (0.48 g, 12 mmol) to the solution at room temperature. Then it slowly added the intermediate 4 (3.10 g, 11 mmol) that dissolved in DMF (20 mL) to the previous mixed solution in 20 min at 60 ∘ C. The reaction mixturewas rapid stirred at 100 ∘ C for 16 h (monitored by TLC). After removal of the solvent under reduced pressure, water (30 mL) was added and extracted with ethyl acetate (3 × 10 mL). Combined organic phase was washed with brine and dried over anhydrous Na 2 SO 4 to give the corresponding crude product, which was purified by flash column chromatography to afford compounds 5a as a pink crystal with yield of 31.5% or 5b as a pink crystal with yield of 29.7%.
General Procedure for the Preparation of 6a and 6b.
To a solution of 5a (600 mg, 1.19 mmol) or 5b (600 mg, 1.23 mmol) in DCM (20 mL) TFA was added (3 mL) at room temperature and the solution was stirred for 5 h. Then the reaction solution was alkalized to PH = 9 with NaHCO 3 . The solution was washed by water (50 mL) and then extracted with DCM (3 × 15 mL). Combined organic phase dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to give the product 6a or 6b. 
General Procedure for the Target Compounds 7a and 7b.
Compound 6a (or 6b) was dissolved in anhydrous DMF (10 mL) in the presence of anhydrous K 2 CO 3 (1.2 eq), followed by addition of appropriate substituted benzyl chloride (bromine, fluorine) (1.1 eq). The reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure, and then water (20 mL) was added. Extracted with ethyl acetate (3 × 10 mL), and the organic phase was washed with saturated sodium chloride (10 mL) then dried over anhydrous Na 2 SO 4 to give the corresponding crude product, which was purified by flash column chromatography to afford compounds 7a1-13 (or 7b1-13). 3H, s,  OCH 3 ), 3.73 (3H, s, OCH 3 ), 3.70 (3H, s), 3.44 (2H, s) , 2.92 (2H, d, J = 6.32 Hz), 2.07-2.09 (4H, m), 1.92 (2H, s).
2-Chloro-9-(1-(4-nitrobenzyl)piperidin-4-yl)-N-(3,4-dimethoxbenzyl)-9H-purin-6-amine (7a4
2-Chloro-9-(1-(3-fluorobenzyl)piperidin-4-yl)-N-(3,4-dimethoxbenzyl)-9H-purin-6-amine (7a5
2-Chloro-9-(1-(pyridine-4-yl-methyl)piperidin-4-yl)-N-(3,4-dimethoxbenzyl)-9H-purin-6-amine (7a6
2-Chloro-9-(1-(3-cyanobenzyl)piperidin-4-yl)-N-(3,4-dimethoxbenzyl)-9H-purin-6-amine (7a9
13 C NMR (100 MHz, DMSO-d6, ppm) : 158.8, 155.3, 153.2, 149.9,  149.0, 148.3, 140.1, 132.1, 130.6, 130.5 (2C), 120.1, 118.9 N- (Benzo[d] [1, 3] 
2-Chloro
-9-(1-(2-fluorobenzyl)piperidin-4-yl)-N-(3,4-dime- thoxbenzyl)-9H-purin-6-amine (7a13dioxol-5-ylmethyl)-2-chloro-9-(1-(3-bromo- benzyl)piperidin-4-yl)-9H-purin-6-amine (7b2N-(Benzo[d][1,3]dioxol-5-ylmethyl)-2-chloro-9-(1-(pyridine- 4-yl-methyl)piperidin-4-yl)-9H-purin-6-amine (7b6
Acetylcholinesterase Inhibition Assay.
The ability of derivatives 7a1-7a13 and 7b1-7b13 to inhibit human acetylcholinesterase (hAChE) (Sigma-Aldrich, USA) was examined using the 5,5 -dithiobis-(2-nitrobenzoic acid) (DTNB) method (to generate a yellow chromophore (5-mercapto-2-nitrobenzoic acid) detectable at the 405-412 nm range) with the acetylcholinesterase assay kit (Keygen, China). The assay was carried out as a previously described protocol [10] using donepezil as controls ( = 4). Stock solutions of test compounds were dissolved in a minimum volume of DMSO (1%) and were diluted using saline. In 96-well plates, 50 L of AChE (0.22 U/mL diluted using saline) was incubated with 10 L of various concentrations of test compounds (1.0, 10.0, 100 M) at room temperature for 10 min followed by the addition of relative agents according to the kit instruction. The absorbance was measured at a wavelength of 405 nm with Thermo MK3 microplate reader. Percent inhibition was calculated by the comparison of compound-treated to various control incubations.
